Dr Elena Zamagni speaks to ecancer about a talk she presented at EMN 2024 on treatment options for late-stage relapsed/refractory multiple myeloma (RRMM). Namely CAR-T, bispecifics or antibody-drug conjugates (ADCs).

She explains that, while these different treatment options are agreed on, the criteria of choice needs to be discussed.

Dr Zamagni details that CAR-T is generally agreed to be for subsets of patients, bispecifics for almost all patients (apart from the elderly and frail) and ADCs for elderly and frail patients.